CAS: 20776-50-5; 2-Amino-4-Bromobenzoic Acid

上下游产品

CAS号99277-71-1 2-硝基-4-溴苯甲酸 | CAS号117323-99-6 2-氨基-4-溴苯甲酸乙酯 | CAS号135484-83-2 2-氨基-4-溴苯甲酸甲酯 | CAS号6326-79-0 6-溴靛红 | CAS号19201-53-7 6,6'-二溴靛蓝 | CAS号106-38-7 对溴甲苯 | CAS号611-00-7 2,4-二溴苯甲酸 | CAS号6941-75-9 4-溴邻苯二甲酰亚胺 | CAS号610-36-6 4-氨基-2-硝基苯甲酸 | CAS号64945-30-8 6-bromo-2-methy... | CAS号112253-70-0 2-氨基-4-溴苯甲酰胺 | CAS号20776-54-9 2-氨基-4-碘苯甲酸 | CAS号959237-68-4 2,4-二氯-7-溴喹唑啉 | CAS号573675-55-5 7-溴-4-氯喹唑啉 | CAS号76561-16-5 4-溴靛红酸酐 | CAS号1265848-98-3 吗啉-7-4-基-3H-喹唑啉-4-酮 | CAS号114703-12-7 7-溴喹唑啉-2,4-二酮 | CAS号135484-83-2 2-氨基-4-溴苯甲酸甲酯 | CAS号1334602-74-2 4-(4-氯喹唑啉-7-基)吗啉 | CAS号201731-79-5 2-溴-9,10-二苯基蒽

6,6'-二溴靛蓝置于(2,2':6',2''-Terpyridine)(Pyridine-2-Carboxylate)Iron(II)Chloride,Sodium Hydroxide体系中,用 水,乙腈 用作溶剂,以88%的收率获得2-氨基-4-溴苯甲酸
参考文献:铁催化选择性合成硝基芳烃和氨基芳烃羧酸的有害染料的碳-碳键裂解和n-氧化过程的设计与机理
标题:铁催化选择性合成硝基芳烃和氨基芳烃羧酸的有害染料的碳-碳键裂解和n-氧化过程的设计与机理
摘要:已经开发了一种有效的铁催化氧化降解方法,该方法是在碱性ph下使用聚合物负载的三溴化物试剂分别将对环境有害的偶氮染料和靛蓝染料分别选择性转化为硝基芳烃和氨基芳烃羧酸(邻氨基苯甲酸).已开发出原位生成的和分离的(定义的)氯-铁(II)-吡啶-吡啶羧酸羧酸盐[fe(tpy)(pic)cl]催化剂体系,并发明了其催化功能用于降解过程.已筛选出不同的氮和氧配体以开发最佳催化剂体系,最后我们一起探索了吡啶2-羧酸和三联吡啶配体,发现是最佳的.值得注意的是,原位已经发现,所产生的和确定的催化剂体系对两种染料的氧化降解具有相似的催化活性是更有效的.结果,整个氧化降解过程都使用fe(tpy)(pic)cl催化剂体系进行,整个过程利用有效的催化方法选择性氧化偶氮和靛蓝的-nn-和-cc-键.染料分别.已经对该反应进行了详细的催化,机理和动力学研究.有趣的是,两种染料都在相同的动力学模式下以共同的氧化降解机理进
Doi:10.1016/j.Molcata.2011.02.002

专利信息

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:US-2015315143-A1
优先权日:2014-05-01
标题 :N-Heterocyclic Carbene-Catalyzed Synthesis of 2-Aryl Indoles

专利号:US-9527812-B2
优先权日:2014-05-01
标题 :N-heterocyclic carbene-catalyzed synthesis of 2-aryl indoles
发明人：SCHEIDT KARL A; HOVEY JR MICHAEL TODD; CHECK CHRISTOPHER
权利人:UNIV NORTHWESTERN
摘要:Transition metal-free catalytic methods for access to 2-arylindole compounds.

专利号:US-9992996-B2
优先权日:2007-09-28
标题 :Bioactive aniline copolymers
发明人：GIZDAVIC-NIKOLAIDIS MARIJA; EASTEAL ALLAN J; STEPANOVIC SRDJAN
权利人:AUCKLAND UNISERVICES LTD
摘要:Aniline copolymers and the synthesis thereof for use as antimicrobial (antibacterial, antifungal or antiviral material) material of for the manufacture of antimicrobial objects, suitable for use in the health, food, packaging, water, paint, wood, textile, poultry, glass, paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. The copolymer may be for example (A): where for example R 3 â•?H 5 —CO 2 H, —CO 2 Me, or —CO 2 Et. R is typically H or a C 1 -C 6 alkyl, x is an integer between 1 and 0 and m indicates the degree of polymerization. Preferred copolymers are copolymers of aniline with 3-aminobenzoic acid, 2-aminobenzoic acid and ethyl 3-aminobenzoate.

专利号:CN-115010671-A
优先权日:2022-07-20
标题:One-step synthesis method of 2-substituted quinazolinone

专利号:US-8461107-B2
优先权日:2008-04-28
标题:HCV NS3 protease inhibitors
发明人：LIVERTON NIGEL J; MCCAULEY JOHN A; BUTCHER JOHN W; GILBERT KEVIN F; MCINTYRE CHARLES J; RUDD MICHAEL T
权利人:LIVERTON NIGEL J; MCCAULEY JOHN A; BUTCHER JOHN W; GILBERT KEVIN F; MCINTYRE CHARLES J; RUDD MICHAEL T; MERCK SHARP & DOHME
摘要:The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.